EcoDrugPlus


Trade Names	ANTABUSE DISULFIRAM DISULFIRAM
Synonyms	Antabuse Disulfiram Esperal NSC-25953 ORA-102 ORA102
Status
Molecule Category	UNKNOWN
ATC	N07BB01 P03AA04
UNII	TR3MLJ1UAI
EPA CompTox	DTXSID1021322

Trade Names

ANTABUSE

DISULFIRAM

Synonyms

Antabuse

Disulfiram

Esperal

NSC-25953

ORA-102

ORA102

Status

Molecule Category

UNKNOWN

ATC

N07BB01 P03AA04

UNII

TR3MLJ1UAI

EPA CompTox

DTXSID1021322


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	AUZONCFQVSMFAP-UHFFFAOYSA-N
Smiles	CCN(CC)C(=S)SSC(=S)N(CC)CC
InChI	InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3

InChI Key

AUZONCFQVSMFAP-UHFFFAOYSA-N

Smiles

CCN(CC)C(=S)SSC(=S)N(CC)CC

InChI

InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3

Mechanism of Action	Action	Reference
Aldehyde dehydrogenase inhibitor	INHIBITOR	Wikipedia DailyMed

Mechanism of Action

Action

Reference

Aldehyde dehydrogenase inhibitor

INHIBITOR

Wikipedia DailyMed

Resources	Reference
ChEBI	4659
ChEMBL	CHEMBL964
DrugBank	DB00822
DrugCentral	928
FDA SRS	TR3MLJ1UAI
Human Metabolome Database	HMDB0014960
Guide to Pharmacology	7168
KEGG	C01692
PharmGKB	PA449376
PubChem	3117
SureChEMBL	SCHEMBL27213
ZINC	ZINC000001529266

Resources

Reference

ChEBI

ChEMBL

DrugBank

DrugCentral

FDA SRS

Human Metabolome Database

HMDB0014960

Guide to Pharmacology

KEGG

PharmGKB

PubChem

SureChEMBL

ZINC


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

DISULFIRAM

Structure

Pharmacology

Cross References